Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 18, 2009 - Issue 2
Submit an article Journal homepage
962
Views
21
CrossRef citations to date
0
Altmetric
Reviews

Cannabinoids against pain. Efficacy and strategies to reduce psychoactivity: a clinical perspective

Matthias Karst Pain Clinic, Hannover Medical School, Department of Anesthesiology, Carl-Neuberg-Street 1, 30625 Hannover, Germany +49 0 5115323108; +49 0 5115328109; [email protected]
, MD PhD &
Sonja Wippermann Pain Clinic, Hannover Medical School, Department of Anesthesiology, Carl-Neuberg-Street 1, 30625 Hannover, Germany +49 0 5115323108; +49 0 5115328109; [email protected]
Pages 125-133 | Published online: 21 Jan 2009

Bibliography

  • Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-4
  • Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-5
  • Jhaveri MD, Sagar DR, Elmes SJR, et al. Cannabinoid CB2 receptor-mediated anti-nociception in models of acute and chronic pain. Mol Neurobiol 2007;36:26-35
  • Devane WA, Hanus L, Breuer R, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;2581:946-49
  • Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995;50:83-90
  • Jonsson KO, Holt S, Fowler CJ. The endocannabinoid system: current pharmacological research and therapeutic possibilities. Basic Clin Pharmacol Toxicol 2006;98:124-34
  • Hohmann AG, Suplita RL. Endocannabinoid mechanisms of pain modulation. AAPS Journal 2006;8:693-708
  • DiMarzo V, De Petrocellis L. Plant, synthetic, and endogenous cannabinoids in medicine. Annu Rev Med 2006;57:553-74
  • Maejima T, Ohno-Shosaku T, Kano M. Endogenous cannabinoid as a retrograde messenger from postynaptic neurons to presynaptic terminals. Neurosci Res 2001;40:205-10
  • Staton PC, Hatcher JP, Walker DJ, et al. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 2008;139(1):225-36
  • Schneider U, Seifert J, Karst M, et al. Das endogene Cannabinoidsystem. Nervenarzt 2005;76:1062-76
  • Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-HT-1A receptors. Neurochemical Research 2005;30(8):1037-43
  • Cravatt BF, Demarest MP, Patricelli MH, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. PNAS 2001;98:9371-6
  • Jhaveri MD, Richardson D, Chapman V. Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br J Pharmacol 2007;152:624-32
  • Fowler CJ. The pharmacology of the cannabinoid system – a question of efficacy and selectivity. Mol Neurobiol 2007;36:15-25
  • Fowler CJ, Holt S, Tiger G. Acidic non-steroidal antiinflammatory drugs inhibit rat brain fatty acid amide hydrolase in a ph-dependent manner. E Enzym Inhib Med Chem 2003;18:55-8
  • Agarwal N, Pacher P, Tegeder I, et al. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 2007;10:870-79
  • Wotherspoon GA, Fox P, Mcintyre S, et al. Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience 2005;35:235-45
  • Romero-Sandoval A, Eisenach JC. Spinal cannabinoid receptor type 2 activation reduces hypersensitivity and spinal cord glial activation after paw incision. Anesthesiology 2007;106:787-94
  • Hohmann AG, Suplita RL, Bolton NM, et al. An endocannabinoid mechanism for stress-induced analgesia. Nature 2005;435:1108-12
  • Naef M, Curatolo M, Petersen-Felix S, et al. The analgesic effect of oral δ9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 2003;105:79-88
  • Kraft B, Frickey NA, Kaufmann RM, et al. Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. Anesthesiology 2008;109:101-10
  • Wallace M, Schulteis G, Atkinson JH, et al. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology 2007;107:785-96
  • Raft D, Gregg J, Ghia J, Harris L. Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Clin Pharmacol Ther 1977;21:26-33
  • Greenwald MK, Stitzer ML. Antinociceptive, subjective and behavioral effects of smoked marijuana in humans. Drug Alcohol Depend 2000;59:261-75
  • Jain AK, Ryan JR, McMahon FG, Smith G. Evaluation of intramuscular Levonantradol and placebo in acute postoperative pain. J Clin Pharmacol 1981;21:320S-326S
  • Holdcroft A, Maze M, Doré C, et al. A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology 2006;104:1040-6
  • Beaulieu P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can J Anesth 2006;53:769-75
  • Buggy DJ, Toogood L, Maric S, et al. Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain 2003;106:169-72
  • Campbell FA, Tramèr MR, Carroll D, et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review BMJ 2001;323:1-6
  • Walker JM, Huang SM. Cannabinoid analgesia. Pharmacol Ther 2002;95:127-35
  • Grant I, Cahn BR. Cannabis and endocannabinoid modulators: therapeutic promises and challenges. Clin Neurosci Res 2005;5:185-99
  • Azad SC, Rammes G. Cannabinoids in anaesthesia and pain therapy. Curr Opin Anaesthesiol 2005;18:424-27
  • Amar MB. Cannnabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol 2006;105:1-25
  • McCarberg BH, Barkin RL. The future of cannabinoids as analgesic agents: a pharmacologic, pharmacokinetic, and pharmacodynamic overview. Am J Ther 2007;14(5):475-83Sep-Oct
  • Russo EB. Cannabinoids in the management of difficult to treat pain. Therapeutics and Clinical Risk Management 2008;4(1):245-59
  • Beaulieu P, Ware M. Reassessment of the role of cannabinoids in the management of pain. Curr Opin Anaesthesiol 2007;20:473-77
  • Noyes R Jr, Brunk SF, Baram DA, Canter A. Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol 1975;15:139-43
  • Petro DJ, Ellenberger C. Treatment of human spasticity with delta-9-tetrahydrocannabinol. J Clin Pharmacol 1981;21:413S-416S
  • Clifford DB. Tetrahydrocannabinol for tremor in multiple sclerosis. Ann Neurol 1983;13:669-71
  • Ungerleider JT, Andrysiak T, Fairbanks L. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 1987;7:39-50
  • Svendson KB, Jensen TS, Back FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? BMJ 2004;329:253-61
  • Holdcroft A, Smith M, Jacklin A, et al. Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia 1997;52:483-88
  • Killestein J, Hoogervorst ELJ, Reif M, et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002;58:1404-07
  • Fox P, Bain PG, Glickman S, et al. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology 2004;62:1105-09
  • Vaney C, Heinzel-Gutenbrunner M, Jobin P, et al. Efficacy, safety, and tolerability of an oral administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004;10:417-24
  • Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicenter randomised placebo-controlled trial. Lancet 2003;362:1517-26
  • Lindstrom P, Lindblom U, Boreus L. Lack of effect of cannabidiol in sustained neuropathia. In: Proceeedings of the Marijuana 1987 International Conference on Cannabis; Sept 2-4; Melbourne, Australia;1987
  • Martyn CN, Illis LS, Thom J. Nabilone in the treatment of multiple sclerosis. Lancet 1995;345:579
  • Pinsger M, Schimetta W, Volc D, et al. Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain: a randomized controlled trial. Wien Klin Wochenschr 2006;118:327-35
  • Wissel J, Haydn T, Muller J, et al. Low dose treatment with the synthetic cannabinoid nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial. J Neurol 2006;253:1337-41
  • Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow-up. J Neurol Neurosurg Psychiatry 2005;76:1664-69
  • Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 2007;68:515-21
  • Tetrault JM, Crothers K, Moore BA, et al. Effects of marijuana smoking on pulmonary function and respiratory complications. Arch Intern Med 2007;167:221-28
  • Guy GW, Robson P. A Phase I, open label, four-way crossover study to compare the pharmacokinetic profiles of a single dose of 20 mg of a cannabis based medicine extract (CBME) administered on 3 different areas of the buccal mucosa and to investigate the pharmacokinetics of CBME per oral in health male and female volunteers (GWPK0112). J Cannabis Ther 2003;3(4):79-120
  • Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers 2007;4(8):1770-804
  • Russo EB, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 2006;66(2):234-46
  • Wade DT, Robson P, House H, et al. A preliminary controlled study to determine whether whole plant cannabis extracts can improve intractable neurogenic symptoms Clin Rehab 2003;17:21-9
  • Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004;10:434-41
  • Notcutt W, Price M, Miller R, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 ‘N of 1’ studies. Anaesthesia 2004;59:440-52
  • Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief on central neuropathic pain from brachial plexus avulsion: results of a randomized controlled trial. Pain 2004;112:299-306
  • Rog DJ, Nurmikko TR, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005;65:812-19
  • Blake DR, Robson P, Ho M, et al. Preliminary assessment of the efficacy, tolerability and safety of cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology 2006;45:50-2
  • Perez-Reyes M. Pharmacodynamics of certain drugs of abuse. In: Barnett G, Chang CN, editors. Pharmacokinetics and pharmacodynamics of psychoactive drugs. Foster City, CA: Biomedical Publishers;1985: p. 287-310
  • Loev B, Bender PE, Dowalo F, et al. Cannabinoids:Structure-activity studies related to 1,2-dimethylheptyl derivatives. J Med Chem 1973;16:1200-06
  • Burstein SH. Inhibitory and stimulatory effects of cannabinoids on eicosanoid synthesis. NIDA Research Monograph 1987;79:158-72
  • Burstein SH, Karst M, Schneider U, Zurier RB. Ajulemic acid: a novel cannabinoid produces analgesia without a ‘high’. Life Sci 2004;75:1513-22
  • Ahrens J, Leuwer M, Demir R, et al. Positive allosteric modulatory effects of ajulemic acid at strychnine-sensitive glycine α1 and α1β receptors. Naunyn Schmiedebergs Arch Pharmacol 2008 (doi: 10.1007/s00210-008-0366-8)
  • Dyson A, Peacock M, Chen A, et al. Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat. Pain 2005;116:129-37
  • Karst M, Salim K, Burstein S, et al. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 2003;290:1757-62
  • Salim K, Schneider U, Burstein S, et al. Pain measurements and side effect profile of the novel cannabinoid ajulemic acid. Neuropharmacology 2005;48:1164-71
  • Sumariwalla PF, Gallily R, Tchilibon S, et al. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine coallagen-induced arthritis. Arthritis Rheum 2004;50:985-88
  • Vann RE, Cook CD, Martin BR, Wiley JL. Cannabimimetic properties of ajulemic acid. J Pharmacol Exp Ther 2007;320:678-86
  • Burstein SH. In humans, ajulemic acid has a more favorable side-effect profile than THC for the treatment of chronic neuropathic pain. Cannabinoids 2007;2(1):1-2
  • Karst M. Comments on ‘Cannabimimetic properties of ajulemic acid'. J Pharmacol Exp Ther 2007;322:420-21
  • Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO. Cannabidiol: recent advances. Chem Biodivers 2007;4(8):1678-92
  • Dziadulewicz EK, Bevan SJ, Brain CT, et al. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration. J Med Chem 2007;50:3851-56
  • Day A. Neuropathic pain: emerging treatments. Br J Anaesth 2008;101:48-58
  • Guindon J, Hohmann AG. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 2008;153:315-34
  • Gertsch J, Leonti M, Raduner S, et al. Beta-caryophyllene is a dietary cannabinoid. Proc Natl Acad Sci USA 2008;105(26):9099-104
  • Fox A, Bevan S. Therapeutic potential of cannabinoid agonists as analgesic agents. Expert Opin Investig Drugs 2005;14:695-703
  • Hanus L, Breuer A, Tchilibon S, et al. HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor. PNAS 1999;96:14228-33
  • Ibrahim MM, Porreca F, Lai J, et al. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. PNAS 2005;102:3093-98
  • Anand U, Otto WR, Sanchez-Herrera D, et al. Cannabinoid receptor CB2 localisation and agonist-mediated inhibition of capsaicin responses in human sensory neurons. Pain 2008;138:667-80
  • Hosking RD, Zajicek JP. Therapeutic potential of cannabis in pain medicine. Br J Anaesth 2008;101:59-68
  • Xu H, Cheng CL, Chen M, et al. Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis. J Leucoc Biol 2007;82:532-41
  • Belvisi MG, Patel HJ, Freund-Michel V, et al. Inhibitory activity of the novel CB2 receptor agonist, GW833972A, on guinea-pig and human sensory nerve function in the airways. Br J Pharmacol 2008;155(4):547-57
  • Idris AI, Sophocleous A, Landao-Bassonga E, et al. Regulation of bone mass, osteoclast function, and ovariectomy-induced bone loss by the type 2 cannabinoid receptor. Endocrinology 2008;149(11):5619-26
  • Calignano A, La Rana G, Giufrida A, Piomelli. Control of pain initiation by endogenous cannabinoids. Nature 1998;394:277-81
  • Sulcova E, Mechoulam R, Fride E. Biphasic effects of anandamide. Pharmacol Biochem Behav 1998;59:347-52
  • Jayamanne A, Greenwood R, Michell VA, et al. Actions of the FAAH inhibitor URB597 in neuropathic pain and inflammatory chronic pain models. Br J Pharmacol 2006;147:281-88
  • Bisogno T, Hanus L, De Petrocellis L, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001;134(4):845-52
  • Wallace VCJ, Segerdahl AR, Lambert DM, et al. The effect of the palmitoylethanolamide analogue, palmitoylallaylamide (L-29) on pain behaviour in rodent models of neuropathy. Br J Pharmacol 2007;151:1117-28
  • Gutierrez T, Farthing JN, Zvonok AM, et al. Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis. Br J Pharmacol 2007;150:153-63
  • Lever IJ, Pheby TM, Rice ASC. Continous infusion of the cannabinoid WIN55,212-2 to the site of a peripheral nerve injury reduces mechanical and cold hypersensitivity. Br J Pharmacol 2007;151:292-302
  • Richardson JD, Kilo S, Hargreaves KM. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 1998;75:111-9
  • Karsak M, Gaffal E, Date R, et al. Attenuation of allergic contact dermatitis through the endocannabinoid system. Science 2007;316(5830):1494-7
  • Rukwied R, Watkinson A, Mcglone F, Dvorak M. Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain 2003;102:283-8
  • Cichewicz DL. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 2004;74:1317-24
  • Yesilyurt O, Dogrul A, Gul H, et al. Topical cannabinoid enhances topical morphine antinociception. Pain 2003;105:303-8

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.